{"id":722,"date":"2022-01-11T14:46:42","date_gmt":"2022-01-11T14:46:42","guid":{"rendered":"https:\/\/bloomnews.wpenginepowered.com\/?p=722"},"modified":"2025-11-12T19:56:30","modified_gmt":"2025-11-12T19:56:30","slug":"new-fda-guidelines-to-speed-up-approval-of-cbd-based-medications","status":"publish","type":"post","link":"https:\/\/blog.bloommarijuana.com\/news\/new-fda-guidelines-to-speed-up-approval-of-cbd-based-medications\/","title":{"rendered":"New FDA Guidelines To Speed Up Approval of CBD-Based Medications"},"content":{"rendered":"\n

The Food and Drug Administration (FDA) is releasing its latest draft guidelines that would speed up the approval process for generic oral CBD medications. In this article I will explain the guidelines and its ramifications for producers of CBD medicines. I will also discuss an upcoming FDA meeting for women and CBD safety, the search by the FDA to find a contractor to study CBD products and FDA help for growers to protect their intellectual property.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The FDA New Guidelines for CBD-Based Medications<\/h2>\n\n\n\n

An in vivo bioequivalence study is typically used by the FDA to ascertain whether a prospective pharmaceutical medication has an equivalent product already in the marketplace. The FDA is allowing CBD companies to request a waiver for this study as long as they meet specific requirements.<\/p>\n\n\n\n

Waiver Qualifications<\/h3>\n\n\n\n
  1. The generic version of 100mg\/ml oral CBD solutions must contain the same active ingredient, the same concentration and the same dosage as the product already on the market known as the Reference Listed Drug (RLD).<\/li>
  2. It may not contain any inactive ingredient nor formula change from the RLD that significantly affects its bioavailability.<\/li>
  3. Any new CBD-based medication must be derived from Cannabis sativa L with a limit of 0.1% THC.<\/li>
  4. To ensure the identity of the botanical raw material (BRM), the following two criteria must be met: